TrialPath

Find a study

Match me to a study

165 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidney

126 studies on the map

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) — AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, AvondaleA Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) — Medical Dermatology Specialists, PhoenixA Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor — Neurocrine Clinical Site, BryantA Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms — Clinical Research Site, BellflowerFibrosis Lessens After Metabolic Surgery — Banner Health Center, PhoenixA Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM — Clinical Trial Site, MontclairA Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity — Parexel International-EPCU Baltimore, BaltimoreEvaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events — Diablo Clinical Research, Inc., Walnut CreekA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) — Mayo Clinic in Arizona, ScottsdaleSafety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant — University of Cincinnati, CincinnatiA Study of LY3971297 in Healthy Participants — CenExel ACT, AnaheimA Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment — UAB Pediatric Endocrinology (Part C and Part D), BirminghamA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort — Research Site, GlendaleEmpagliflozin Treatment in Kidney Transplant Recipients — Edward Hines Jr. VA Hospital, Hines, IL, HinesStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma — Stanford, Palo AltoA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity — MBX Biosciences Investigational Site, DoralEffect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity — Fortrea Clinical Research Unit - Daytona Beach, Daytona BeachTirzepatide in PWS, HO and GNSO — Children's Minnesota, Saint PaulA Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity — Fortrea Clinical Research Unit - Daytona Beach, Daytona BeachA Study of LY4064912 in Healthy Participants and With Overweight or Obesity — Collaborative Neuroscience Network - CNS, Los AlamitosA Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity. — Research Site, GlendaleStudy of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) — Qps-Mra, Llc., MiamiA Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) — Panax Clinical Research ( Site 0003), Miami LakesENA-001 for Opioid Induced Respiratory Depression — South Florida Research Phase I-IV, MiamiMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoA Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity — CenExel ACT- Anaheim Clinical Trials /ID# 283200, AnaheimA Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets — Corxel Investigational site, Las VegasA Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet — Advent Health-Res Inst, OrlandoStudy of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D — Clinical Pharmacology of Miami, MiamiA Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy — Fortrea Clinical Research Unit, MadisonA Study on How NNC0174-1213 Works in People With Overweight or Obesity. — ICON Early Phase Services, LLC, San AntonioUse of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use — 46 Centerra Parkway, Suite 300, Office #333S, LebanonInvestigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism — Biomedical Research Imaging Center Marsico Hall (UNC), Chapel HillA Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function — Floridian Clinical Research, LLC, Miami LakesA Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease — Floridian Clinical Research, Miami LakesPioglitazone to Reduce Sympathetic Overactivity in CKD Patients — University of Texas at Arlington, ArlingtonStudy to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD — Northwestern Memorial Hospital, ChicagoSafety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease — Quotient Sciences Sea View, MiamiOral Iron in Children With Chronic Kidney Disease — Weill Cornell Medicine / New York Presbyterian Hospital, New YorkA Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD) — SouthCoast Research Center, Inc., MiamiGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression — Wells Medicine, HoustonFeasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department — University of Kansas Strawberry Hill Campus, Kansas CityKetamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients — Texas Tech University Health Sciences Center Lubbock, LubbockBuspirone and Melatonin for Depression Following Traumatic Brain Injury — Massachusetts General Hospital, BostonAβ Dynamics in LLMD — NYU Langone Health, New YorkSafety of Short-course of NSAIDs in Pediatric Patients With CKD — Children's Hospital Colorado, AuroraWeight Loss Study: Genetics and Response to Naltrexone/Bupropion — Columbia University Medical Center, New YorkSafety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity — California Clinical Trials Medical Group, GlendaleSemaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants — Celerion Clinical Research, TempeMetabolic Effects of Angiotensin-(1-7) — Vanderbilt University Medical Center, NashvilleFirst in Human Study in Subjects With Obesity, But Otherwise Healthy — Clinical Pharmacology of Miami, LLC, MiamiUse of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome — University of Colorado Anschutz Medical Campus, AuroraA Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults — Frontage Clinical Services, Inc., SecaucusA Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants — Medpace Clinical Pharmacology Unit, CincinnatiA Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes — Altasciences Clinical Los Angeles, Inc., CypressFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaTirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors — Weill Cornell Medicine, New YorkPioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants — Texas Diabetes Institute/UH, San AntonioOptimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease — Cleveland Clinic Main Campus, ClevelandVaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates. — Inova Health System, Falls ChurchA Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight — Altasciences Clinical Kansas, Inc., Overland ParkThe Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity — Mayo Clinic in Florida, JacksonvillePilot Testing a Novel Approach to Pediatric Obesity Treatment — Texas Tech University, LubbockPharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery — University of California Irvine Medical Center, OrangeGLP-1R Actions on Muscle and the Skeleton — Pennington Biomedical Research Center, Baton Rouge2024 Tirzepatide-Bariatric Surgery — University of Kentucky, LexingtonA Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity — PAREXEL Glendale/LA EPCU, GlendaleA Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity — ICON Early Phase Services, LLC, LenexaProject SHINE (Sleep Health INitiative for Equity): Culturally Informing a Sleep Extension Intervention for African American Adults — University of Minnesota, MinneapolisEvaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects — Pharmaron CPC, Inc, BaltimoreMitigating the Pro-inflammatory Phenotype of Obesity — University of Kansas Medical Center, Kansas CityImpact GLP-1 Agonists Following Bariatric — University of Missouri Hospital, ColumbiaPharmacogenetics of Response to GLP1R Agonists — Amish Research Clinic, LancasterA Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity — Pfizer Clinical Research Unit - New Haven, New HavenDiazoxide Suppression Test P&F Study — Columbia University Irving Medical Center, New YorkSympathetic Mechanisms in Obesity-Crossover Design — Vanderbilt University Medical Center, NashvillePhysiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents — Childrens Hospital Colorado, AuroraA Self-Guided Mobile Intervention for Adults With Binge Eating and Obesity — Drexel University, PhiladelphiaGraded Insulin Suppression Test P&F — Columbia University Irving Medical Center, New YorkPrevention of Progression of Prediabetes, Obesity and CV Risk — University of Texas Health Science Center at San Antonio, San AntonioExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) — Altasciences Clinical LA, Inc., CypressDevelopment of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients — Yale University, New HavenThe Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function — Vanderbilt University Medical Center, NashvilleHuman Models of Selective Insulin Resistance: Alpelisib, Part I — Columbia University Irving Medical Center, New YorkIndividualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder — Mayo Clinic, RochesterA Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects — ProSciento, INC, Chula VistaThe Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics — University of Kentucky, LexingtonEffect of Insulin Lowering on Lipogenesis — Columbia University Irving Medical Center, New YorkPhysiologic Markers of Cardiometabolic Risk in People With Type 1 Diabetes — Yale Pediatric Diabetes Research, New HavenEvaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women — Pharmaron CPC, Inc, BaltimoreMechanism of SGLT2 Inhibition in the Kidney — University of Michigan, Ann ArborDelayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants — UCLA, Los AngelesEffect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease — Northwestern University, ChicagoBZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants — Ohio State University Comprehensive Cancer Center, ColumbusEffect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD — Washington DC Veterans Affairs Medical Center (688), Washington D.C.AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses — Mayo Clinic in Florida, JacksonvilleSympatholysis in Chronic Kidney Disease — Atlanta VA Medical Center, DecaturAdia Med of Winter Park LLC Chronic Kidney Disease Research Study — Adia Med Of Winter Park, Winter ParkStudy to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD — New York University Langone Health, New YorkBreakthrough - T1DM and Chronic Kidney Disease — The University of Chicago, ChicagoAcute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A) — University of Cincinnati, CincinnatiOvarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression — University of North Carolina, Chapel Hill, Chapel HillPattern Separation in Major Depressive Disorder — New York State Psychiatric Institute (NYSPI), New YorkDBS for Depression — Zucker Hillside Hospital, QueensProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression — Laureate Institute for Brain Research, TulsaIdentifying and Treating Depression in the Orthopaedic Trauma Population — Wake Forest University Health Sciences, Winston-SalemNeuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder — National Institutes of Health Clinical Center, BethesdaPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityPsilocybin in Chronic Low Back Pain and Depression — Johns Hopkins University School of Medicine, BaltimoreEstablishing Multimodal Brain Biomarkers for Treatment Selection in Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinModulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains — Lindner Center of Hope, MasonDopaminergic Therapy for Anhedonia - 2 — Emory University Hospital, AtlantaAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesSerotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures — Wake Forest University Health Sciences, Winston-SalemDetermining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, Cincinnati[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET — National Institutes of Health Clinical Center, BethesdaLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression — Massachusetts General Hospital, BostonStudy of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans — Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West HavenRCT of Psilocybin-assisted CBT for Depression — UCLA Semel Institute, Los AngelesPsilocybin to Treat Depression in Spinal Cord Injury — James J. Peters Department of Veterans Affairs Medical Center, The BronxPET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD) — National Institutes of Health Clinical Center, BethesdaPET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine. — Stony Brook University: Dept of Psychiatry, Stony BrookRNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) — Mayo Clinic in Rochester, RochesterEffects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression — Laureate Institute for Brain Research, TulsaPharmacologic Augmentation of TMS for Depression With D-serine — McLean Hospital, BelmontNeural Response to Inflammatory Challenge in Major Depressive Disorder — Laureate Institute for Brain Research, Tulsa

Showing the 150 nearest — narrow your filters for fewer, closer studies.